Repression of interleukin-2 and interleukin-4 promoters by tumor suppressor protein p53

Journal of Interferon and Cytokine Research

Volumn 16, Issue 8, 1996, Pages 595-600

  Pesch, Jürgen ^a   Brehm, Ursula ^a   Staib, Caroline ^a   Grummt, Friedrich ^a,b  

^a UNIVERSITY OF WÜRZBURG   (Germany)

^b UNIVERSITY OF WÜRZBURG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

HIGH MOBILITY GROUP PROTEIN; INHIBITOR PROTEIN; INTERLEUKIN 2; INTERLEUKIN 4; IONOMYCIN; LUCIFERASE; PHORBOL 13 ACETATE 12 MYRISTATE; PROTEIN P53;

ANIMAL CELL; ARTICLE; CONTROLLED STUDY; DELETION MUTANT; GENE REPRESSION; HUMAN; HUMAN CELL; LEUKEMIA CELL LINE; LYMPHOMA CELL; MOUSE; NONHUMAN; OLIGOMERIZATION; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN DOMAIN; TUMOR SUPPRESSOR GENE;

ANIMALIA; MURINAE; SIMIAE; SIMIAN VIRUS; SIMIAN VIRUS 40;

EID: 0029793416     PISSN: 10799907     EISSN: None     Source Type: Journal    
DOI: 10.1089/jir.1996.16.595     Document Type: Article

References (45)

1. YOKOTA, T., ARAI, N., DE VRIES, J., SPLITS, H., BANCHEREAU, J., ZLOTNIK, A., RENNICK, D., HOWARD, M., TAKABE, Y., MIYATAKE, S., LEE, F., and ARAI, K.-I. (1988). Molecular biology of interleukin 4 and interleukin 5 gene and biology of their products that stimulate B cells, T cells and hemopoiietic cells. Immunol. Rev. 102, 137-187.
2. KRÖNKE, M., LEONARD, W.J., DEPPER, J.M., and GREENE, W.C. (1985). Sequential expression of the genes involved in human T lymphocyte growth and expression. J. Exp. Med. 161, 1593-1598.
3. DURAND, D.B., SHAW, J.P., BUSH, M.R., REPLOGLE, R.E., BELAGAJE, R., and CRABTREE, G.R. (1988). Characterization of antigen receptor response elements within the interleukin-2 enhancer. Mol. Cell. Biol. 8, 1715-1724.
4. FRASER, J.D., IRVING, B.A., CRABTREE, G.R., and WEISS, A. (1991). Regulation of interleukin-2 gene enhancer activity by the T cell accessory molecule CD28. Science 251, 313-316.
5. HOYOS, B., BALLARD, D.W., BOHNLEIN, E., SIKEVITZ, M., and GREENE, W.C. (1989). Kappa β-specific DNA binding proteins: role in the regulation of human interkukin-2 gene expression. Science 214, 457-460.
6. JAIN, J., VALGE ARCHER, V.E., and RAO, A. (1992). Analysis of the AP-1 sites in the IL-2 promoter. J. Immunol. 148, 1240-1250.
7. KAMPS, M.P., CORCORAN, L., LEBOWITZ, J.H., and BALTIMORE, D. (1990). The promoter of the human interleukin-2 gene contains two octamer-binding sites and is partially activated by the expression of Oct-2. Mol. Cell. Biol. 10, 5464-5472.
8. SERFLING, E., BARTHELMAS, R., PFEUFFER, I., SCHENK, B., ZARIUS, S., SWOBODA, R., MERCURIO, F., and KARIN, M. (1989). Ubiquitous lymphocyte-specific factors are involved in the induction of the mouse interleukin-2 gene in T lymphocytes. EMBO J. 8, 465-173.
9. SHAW, J.P., UTZ, P.J., DURAND, D.B., TOOLE, J.J., EMMEL, E.A., and CRABTREE, G.R. (1988). Identification of a putative regulator of early T cell activation genes. Science 241, 202-205.
10. C. Mol. Cell. Biol. 13, 4793-4805.
11. KUBO, M., KINCAID, R.L., and RANSOM, J.T. (1994). Activation of the interleukin-4 gene is controlled by the unique calcineurin-dependent transcriptional factor NF(P). J Biol. Chem. 269, 19441-19446.
12. CHUVPILO, S., SCHOMBERG, C., GERWIG, R., HEINFLING, A., REEVES, R., GRUMMT, F., and SERFLING, E. (1993). Multiple closely linked NFAT/octamer and HMG I(Y) binding sites are part of the interleukin-4 promoter. Nucleic Acids Res. 21, 5694-5704.
13. WEGNER, M., ZASTROW, G., KLAVINIUS, A., SCHWENDER, S., MÜLLER, F., LUKSZA, H., HOPPE, J., WIENBERG, J., and GRUMMT, F. (1989). Cis-acting sequences from mouse rDNA promote plasmid DNA amplification and persistance in mouse cells: implication of HMG-1 in their function. Nucleic Acids Res. 17, 9909-9932.
14. BARGONETTI, J., FRIEDMAN, P., KERN, S., VOGELSTEIN, B., and PRIVES, C. (1991). Wild-type but not mutant p53 immunopurified proteins bind to sequences adjacent to the SV40 origin of replication. Cell 65, 1083-1091.
15. KERN, S., KINZLER, K., BRUSKIN, A., JAROSZ, D., FRIEDMAN, P., PRIVES, C., and VOGELSTEIN, B. (1991). Identification of p53 as a sequence-specific DNA-binding protein. Science 256, 1708-1711.
16. FARMER, G., BARGONETTI, J., ZHU, H., FRIEDMAN, P., PRYWES, R., and PRIVES, C. (1992). Wild-type p53 activates transcription in vitro. Nature (Lond.) 358, 83-86.
17. KERN, S., PIETENPOL, J., THIAGALINGAM, S., SEYMOUR, A., KINZLER, K., and VOGELSTEIN, B. (1992). Oncogenic forms of p53 inhibit p53-regulated gene expression. Science 256, 827-830.
18. ZAMBETTI, G., BARGONETTI, J., WALKER, K., PRIVES, C., and LEVINE, A. (1992). Wild-type p53 mediates positive regulation of gene expression through a specific DNA sequence element. Genes Dev. 6, 1143-1152.
19. FUNK, W.D., PAK, D.T., KARAS, R.H., WRIGHT, W.E., and SHAY, J.W. (1992). A transcriptionally active DNA-binding site for human p53 protein complexes. Mol. Cell. Biol. 12, 2866-2871.
20. GINSBERG, D., MECHTA, F., YANIV, M., and OREN, M. (1991). Wild-type p53 can down-modulate the activity of various promoters. Proc. Natl. Acad. Sci. USA 88, 9979-9983.
21. MERCER, W., SHIELDS, M., LIN, D., APELLA, E., and ULLRICH, S. (1991). Growth suppression induced by wild-type p53 is accompanied by selective down-regulation of proliferating-cell nuclear antigen expression. Proc. Natl. Acad. Sci. USA 88, 1958-1962.
22. RAGIMOV, N., KRAUSKOPF, A., NAVOT, N., ROTTER, V., OREN, M., and ALONI, Y. (1993). Wild-type but not mutant p53 can repress transcription initiation in vitro by interfering with the binding of basal transcription factors of the TATA motif. Oncogene 8, 1183-1193.
23. SANTHANAM, U., RAY, A., and SEHGAL, P.B. (1991). Repression of the interleukin 6 gene promoter by p53 and the retinoblastoma susceptibility gene product. Proc. Natl. Acad. Sci. USA 88, 7605-7609.
24. SETO, E., USHEVA, A., ZAMBETTI, G., MOMAND, J., HORIKOSHI, R., WEINMANN, R., LEVINE, A., and SHENK, T. (1992). Wild-type p53 binds to the TATA-binding protein and represses transcription. Proc. Natl. Acad. Sci. USA 89, 12028-12032.
25. SHIIO, Y., YAMAMOTO, T., and YAMAGUCHI, N. (1992). Negative regulation of RB expression by the p53 gene product. Proc. Natl. Acad. Sci. USA 89, 5206-5210.
26. SUBLER, M., MARTIN, D., and DEB, S. (1992). Inhibition of viral and cellular promoters by human wild-type p53. J. Virol. 66, 47577-1762.
27. LEVY, N., YONISH-ROUACH, E., OREN, M., and KIMCHI, A. (1993). Complementation by wild-type p53 of interleukin-6 effects on M1 cells: induction of cell cycle exit and cooperativity with c-myc suppression. Mol. Cell. Biol. 13, 7942-7952.
28. YONISH-ROUACH, E., GRUNWALD, D., WILDER, S., KIMCHI, A., MAY, E., LAWRENCE, J.J., MAY, P., and OREN, M. (1993). p53-mediated cell death: relationship to cell cycle control. Mol. Cell. Biol. 13, 1415-1423.
29. 1 arrest. Cell 76, 1013-1023.
30. MIYASHTA, T., KRAJEWSKI, S., KRAJEWSKA, M., WANG, H.G., LIN, H.K., LIEBERMANN, D.A., HOFFMAN, B., and REED, J.C. (1994). Tumor suppressor p53 is a regulator of bcl-2 and bax gene expression in vitro and in vivo. Oncogene 9, 1799-1805.
31. SELVKUMARAN, M., LIN, H.-K., MIYASHITA, T., WANG, H.G., KRAJEWSKI, S., REED, J.C., HOFFMAN, B., and LIEBERMANN, D. (1994). Immediate early up-regulation of bax expression by p53 but not TGFβ: a paradigm for distinct apoptotic pathways. Oncogene 9, 1791-1798.
32. cdc2 expression and normal p53 suppresses cyclin A expression. Exp. Cell Res. 210, 94-101.
33. LIU, X., MILLER, C., KOEFFLER, P., and BERK, A. (1993). The p53 activation domain binds the TATA box-binding polypeptide in Holo-TFIID, and a neighboring p53 domain inhibits transcription. Mol. Cell. Biol. 13, 3291-3300.
34. TRUANT, R., XIAO, H., INGLES, C., and GREENBLATT, J. (1993). Direct interaction between the transcriptional activation domain of human p53 and TATA-box-binding protein. J. Biol. Chem. 268, 2284-2287.
35. DE WET, J.R., WOOD, K.V., DELUKA, M., HELINSKI, D.R., and SUBRAMANI, S. (1987). Firefly luciferase gene: structure and expression in mammalian cells. Mol. Cell. Biol. 7, 725-737.
36. STAIB, C., PESCH, J., GERWIG, R., GERBER, J.-K., BREHM, U., STANGEL, A., and GRUMMT, F. (1996). p53 inhibits JC virus DNA replication in vivo and interacts with JC virus large T antigen. Virology 219, 237-246.
37. GREEN, S., and CHAMBON, R. (1988). A versatile in vivo and in vitro eukaryotic expression vector for protein engeneering. Nucleic Acids Res. 16, 369-375.
38. SUBLER, M.A., MARTIN, D.W., and DEB, S. (1994). Overlapping domains on the p53 protein regulate its transcriptional activation and repression functions. Oncogene 9, 1351-1359.
39. FIELDS, S., and JANG, S.K. (1990). Presence of potent transcriptional activating sequence in the p53 protein. Science 249, 1046-1049.
40. SHAULIAN, E., ZAUBERMAN, A., MILNER, J., DAVIES, E.A., and OREN, M. (1993). Tight DNA binding and oligomerization are dispensable for the ability of p53 to transactive target genes and suppress transformation. EMBO J. 12, 2789-2797.
41. JACKSON, P., RIDGWAY, P., RAYNER, J., NOBLE, J., and BRAITHWAITE, A. (1994). Transcriptional regulation of the PCNA promoter by p53. Biochem. Biophys. Res. Commun. 203, 133-140.
42. KLEY, N., CHUNG, R.Y., FAY, S., LOFFLER, J.P., and SEIZINGER, B.R. (1992). Repression of the basal c-fos promoter by wild-type p53. Nucleic Acids Res. 20, 4083-4087.
43. DONEHOWER, L.A., HARVEY, M., SLAGLE, B.L., McARTHUR, M.J., MONTGOMERY, C.A., BUTEL, J.S., and BRADLEY, A. (1992). Mice deficient for p53 are developmentally normal but susceptible to spontaneous tumors. Nature 356, 215-221.
44. HECHT, F., and HECHT, B.K. (1990). Cancer in ataxia-telangiectasia patients. Cancer Genet. Cytogenet. 46, 9-19.
45. KASTAN, M.B., ZHAN, Q., EL-DEIRY, W., CARRIER, F., JACKS, T., WALSH, W.V., PLUNKETT, B.S., VOGELSTEIN, B., and FORNACE, A.J., Jr. (1992). A mammalian cell cycle checkpoint pathway utilizing p53 and GADD45 is defective in ataxia-telangiectasia. Cell 71, 587-597.